TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06070012: Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Sponsor: Diwakar Davar · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 44 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT06070012 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06070012 Rescue Dossier →